Orthopedic Biomaterials Market Size, Share & Trends Analysis - United States - 2024-2030 - MedSuite - Includes: Bone Graft Substitutes, Orthopedic Growth Factors, Cellular Allografts, and 3 more
Product Description
In 2023, the U.S. orthopedic biomaterials market was valued at over $5.0 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching over $7.2 billion during the forecast period. The comprehensive report on the U.S. market for orthopedic biomaterials covers various segments, including bone graft substitutes (allografts, demineralized bone matrices (DBMs), xenografts, and synthetic bone grafts). The report also encompasses orthopedic growth factors, cellular allografts, orthopedic cell therapy (bone marrow aspirate concentrate and platelet-rich plasma), hyaluronic acid (HA) viscosupplementation (single-, two-, three-, and five-injection cycles), and orthopedic cartilage repair. The cartilage repair segment includes osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, particulated juvenile allografts, and microfracture adjuncts.
DATA TYPES INCLUDEDUnit Sales, Average Selling Prices, Market Value & Growth Trends
Forecasts Until 2030, and Historical Data to 2020
Market Drivers & Limiters for Each Segment
Competitive Analysis with Market Shares for Each Segment
Recent Mergers & Acquisitions
COVID-19 Impact on the Digital Dentistry market
Disease Overviews and Demographic Information
Company Profiles, Product Portfolios and SWOT for Top Competitors
U.S. Orthopedic Biomaterials Market InsightsThe orthopedic biomaterials market is heavily influenced by demographic trends, especially the aging population and the increasing incidence of osteoarthritis (OA) in the spine. The rise in spinal fusion procedures is closely linked to the growing number of OA cases, which correlate with advancing age. Since the first wave of baby boomers began retiring in 2008, the population at risk for degenerative diseases has expanded, increasing the demand for treatments such as bone grafts.
As the elderly population continues to grow and obesity rates remain high, the prevalence of degenerative diseases is expected to rise. This demographic shift underscores a heightened need for orthopedic biomaterials and restorative procedures, driving market growth throughout the forecast period.
U.S. Orthopedic Biomaterials Market Share InsightsIn the U.S. orthopedic biomaterials market, three main competitors dominate: Medtronic, DePuy Synthes, and Stryker.
Medtronic maintained its leading position in 2023, particularly excelling in the bone graft substitute segment and the growth factor market with its successful INFUSE™ product.
DePuy Synthes held the second-largest market share, a position it has consistently maintained. The company demonstrated significant strength in the bone graft substitute and cellular allograft segments and also distributed the leading hyaluronic acid product. DePuy Synthes offers a demineralized bone matrix (DBM) product processed by the Musculoskeletal Transplant Foundation (MTF) and the DBX® product line, which complements its spinal hardware business. The DBX line includes an osteoinductive and osteoconductive bone graft substitute combined with DBM. Additionally, DePuy Synthes distributes Monovisc® and Orthovisc®, single- and three-injection hyaluronic acid products manufactured by Anika Therapeutics.
Stryker secured the third-largest market share, supported by its extensive product portfolio in the bone graft substitute, growth factor, and cellular allograft markets. This position was largely achieved through strategic acquisitions of several previous competitors.
MARKET SEGMENTATION SUMMARYU.S. Orthopedic Bone Graft Substitute Market – MedCore – Includes:
Material Type: Autograft, Allograft, Xenograft, Demineralized Bone Matrix, Synthetic.
U.S. Orthopedic Growth Factor Market– MedCore – Includes:
Indication Type: Cervical disc Degeneration, Tibial, Spinal, Ankle & Hindfoot.
Care Setting: Hospital, Non-Hospital.
U.S. Orthopedic Cellular Allograft Market– MedCore – Includes:
Anatomy Type: Cervical Spine, Lumbar Spine, Foot & Ankle Allograft, Trauma Allograft.
Patient Type: Pediatric/Neonatal, Adult.
Care Setting: Hospital, Non-Hospital.
U.S. Orthopedic Cell Therapy Market– MedCore – Includes:
Material Type: Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate.
Patient Type: Pediatric/Neonatal, Adult.
U.S. Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:
Injection Cycle Type: Single, Two, Three, Five-Injection.
Patient Type: Pediatric/Neonatal, Adult.
Care Setting: Hospital, Non-Hospital.
U.S. Orthopedic Cartilage Repair Market– MedCore – Includes:
Treatment Type: Microfracture, OATS, Osteochondral Allograft, Meniscal Allograft, Autologous Chondrocyte Implantation, Particulated Juvenile Allograft, Microfracture Adjunct.
Patient Type: Pediatric/Neonatal, Adult.
Care Setting: Hospital, Non-Hospital.